Denifanstat
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sagimet Biosciences Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06594523CT.gov A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis | — | Withdrawn | — | — | — |
NCT06692283CT.gov A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | — | Withdrawn | — | — | — |
NCT04906421CT.gov Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT03938246CT.gov Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Denifanstat (this asset) | Sagimet Biosciences Inc. | P3 | BB · 66 |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Exenatide | Fudan University | P4 | BBB |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BBB |
| Clesacostat | Columbia University | P2 | BB |
| Ervogastat | Pfizer | P2 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for Denifanstat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P3 | BB · 64 |
| Breast Carcinoma | — | P2 | B · 57 |
| Breast Cancer | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Denifanstat in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/denifanstat-metabolic-dysfunction-associated-steatotic-liver-disease-96346
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →